Any content you receive is for information purposes only. Always conduct your own research.

*Disseminated on Behalf of Medicus Pharma Ltd.

Daily Edge Report Puts (MDCX) On Tomorrow's

Watchlist—Friday, February 13, 2026

Don't miss the next breakout — get real-time alerts sent straight to your phone!

Full Coverage Starts In The Morning

Take A Look At (MDCX) Before Tomorrow Morning…

February 12, 2026

Friday's Focus | See Why (MDCX) Will Be Topping Tomorrow's Watchlist

Dear Reader,

In clinical-stage biotech, real momentum doesn't always start with data, sometimes it starts with a regulatory green light.

That's the stage Medicus Pharma Ltd. (NASDAQ: MDCX) has just stepped into.

The company announced that the U.S. FDA has granted a "study may proceed" clearance for its Phase 2b dose-optimization trial of Teverelix® in men with advanced prostate cancer who also carry high cardiovascular risk, a patient population that remains underserved by many traditional hormone therapies.

In the development biotech world, FDA clearance at this level is more than procedural, it signals regulatory alignment on trial design and allows the company to advance into a more defined execution phase, potentially positioning Teverelix for Phase 3 progression if outcomes are supportive.

With these dynamics unfolding, (MDCX) is positioned to headline our watchlist tomorrow morning — Friday, February 13, 2026.

It's also worth noting that (MDCX) is operating with an ultra-thin float of under 9M shares, according to MarketWatch. In micro-cap biotech, limited float can amplify volatility, meaning shifts in demand can translate into outsized movement when momentum builds.

Layer in insider ownership north of 30%, a level that often reflects meaningful internal alignment, and the share structure becomes even tighter from a trading perspective. That combination is one reason momentum-focused traders have started revisiting the name.

On the coverage front, multiple outlets, including Benzinga, have reported that D. Boral Capital set a $27 target on (MDCX). From its recent $0.99 range, that target implies approximately 2,630% upside potential, based on current levels.

Taken together, tight float, insider alignment, regulatory progress, and active analyst coverage, the setup is one that warrants a closer look.

Precision Therapeutics Poised for Clinical and Commercial Impact

Medicus Pharma Ltd. (NASDAQ: MDCX) is a clinical-stage biotechnology company focused on advancing next-generation therapies for prostate cancer and skin cancer while leveraging strategic acquisitions and innovative delivery technologies to broaden its pipeline.

At the core of its oncology efforts is Teverelix®, a long-acting gonadotropin-releasing hormone (GnRH) antagonist acquired through the acquisition of clinical-stage dr-ug developer Antev Limited in 2025. Teverelix is designed to rapidly suppress testosterone without the initial hormone surge common with older therapies, potentially reducing cardiovascular risk in men with advanced prostate cancer and high cardiovascular risk.

Alongside Teverelix, Medicus is advancing SkinJect™, an investigational dissolvable microneedle array (D-MNA) patch intended to non-invasively deliver a chemotherapeutic agent directly into basal cell carcinoma (BCC) lesions. This platform aims to reduce the need for surgical excision and improve patient outcomes through localized treatment in non-melanoma skin cancer.

Both programs reflect (MDCX)'s focus on precision-guided therapeutics, targeting high-impact oncology segments with differentiated mechanisms and clinical pathways supported by ongoing regulatory engagement.

In tandem with product development, Medicus has pursued collaborations to accelerate clinical execution, including engagement on AI-driven data analytics to optimize trial design and operational efficiency.

Key Developments Driving the 2026 Setup

FDA Clears Teverelix Phase 2b Study: (MDCX) announced that the U.S. Food and Dr-ug Administration has granted "study may proceed" clearance for its Phase 2b dose-optimization trial of Teverelix® in men with advanced prostate cancer and high cardiovascular risk. The open-label study is designed to enroll approximately 40 patients and evaluate sustained hormone suppression and safety outcomes, positioning the program for a registrational Phase 3 pathway if successful.

Enrollment Completed for Phase 2 SkinJect Trial: (MDCX) confirmed that it completed enrollment of 90 patients in its U.S. Phase 2 clinical study (SKNJCT-003) evaluating its SkinJect™ dissolvable microneedle array (D-MNA) for basal cell carcinoma (BCC). Topline results from this trial are expected before the end of Q1 2026, followed by an End-of-Phase 2 meeting with the FDA in H1 2026.

Expanded Regulatory Footprint and Presentations: (MDCX) executives presented at Biotech Showcase 2026, highlighting its Phase 2 clinical data progression and partnering readiness, as the company enters 2026 with multiple catalysts and regulatory optionality across its pipeline.

AI-Driven Development Initiatives: In late 2025, (MDCX) announced a non-binding Letter of Intent (LOI) with Reliant AI to develop an AI-driven clinical data analytics platform aimed at improving trial design, site selection, patient stratification, and enrollment forecasting for Teverelix and other programs.

These developments reflect execution across clinical, regulatory, and operational fronts as (MDCX) advances its key programs toward potential value inflection points in 2026.

Strengthening the Corporate Foundation

Beyond clinical and regulatory progress, (MDCX) has continued reinforcing its corporate positioning as it advances its pipeline.

In January 2026, (MDCX) marked its one-year anniversary as a Nasdaq-listed issuer with an Opening Bell ceremony, a symbolic milestone that highlighted progress across its development programs while signaling continued efforts toward strategic partnerships and long-term commercialization pathways.

At the same time, (MDCX) has taken steps to support its balance sheet through warrant inducement agreements, designed to encourage the exercise of outstanding warrants and generate additional capital. These activities can provide incremental funding to support ongoing clinical execution and operational initiatives.

(MDCX) has also expanded its market visibility efforts, entering into media and market awareness agreements aimed at broadening institutional and analyst engagement. Increased visibility can play an important role for micro-cap biotech companies as they approach key data readouts and regulatory inflection points.

Taken together, these corporate actions reflect a parallel strategy: advancing the science while strengthening capital structure and market awareness.

6 Reasons Why (MDCX) Will Be Topping Our Watchlist Tomorrow Morning—Friday, February 13, 2026

1. FDA Clearance: The FDA has cleared (MDCX) to proceed with its Phase 2b dose-optimization study of Teverelix® in advanced prostate cancer patients with high cardiovascular risk. Regulatory alignment at this stage is a meaningful step toward potential Phase 3 progression.

2. Analyst Target: D. Boral Capital has published a $27 target on (MDCX). From recent levels around $1, that represents a 2,630% upside potential.

3. Small Float Structure: (MDCX) is working with a float under 9M shares. In micro-cap biotech, limited float can amplify movement when volume increases and attention builds.

4. Insider Ownership Alignment: Insiders control a meaningful percentage of shares outstanding, creating tighter effective supply and signaling internal alignment with long-term program development.

5. AI-Driven Clinical Optimization Strategy: (MDCX) has engaged in AI-driven clinical analytics initiatives designed to enhance trial efficiency, site selection, and patient stratification, targeting operational execution at a critical development stage.

6. Dual Late-Stage Pipeline Exposure: Following the acquisition of Antev Limited, (MDCX) now has two late-stage programs addressing prostate cancer and basal cell carcinoma, expanding its therapeutic footprint and potential catalyst.

Take A Look At (MDCX) Before Tomorrow Morning…

With multiple dynamics converging at once, (MDCX) finds itself in a tightly structured position, supported by a float under 9M shares and a history of sharp percentage moves when volume accelerates.

Analyst coverage remains notably aggressive relative to current levels. With shares recently around the $0.99 range, published targets stretching as high as $27 imply substantial theoretical upside if execution and clinical milestones advance as modeled.

Layer in meaningful insider ownership, recent FDA clearance to proceed with the Phase 2b Teverelix study, expanding clinical activity, and a pipeline now anchored by two late-stage therapeutic programs, and it's clear this is not a story fading into the background.

The combination of regulatory progress, structural dynamics, and analyst modeling is why (MDCX) will be front and center on our watchlist tomorrow morning.

(MDCX) is one worth reviewing before you call it a night.

We'll be back early with further updates.

Sincerely,

Joel Locke

Senior Editor

The Daily Edge Report

^{DailyEdgeReport.com}^{("DailyEdgeReport" or "DER" ) is owned by GG Media Holdings LLC, a multi member limited liability company. Data is provided from third-party sources and DER is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile DER brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.}

^{Pursuant to an agreement between GG Media Holdings LLC and TD Media LLC, GG Media Holdings LLC has been hired for a period beginning on 02/12/2026 and ending on 02/13/2026 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, TD Media LLC has paid GG Media Holdings LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, GG Media Holdings LLC has been paid thirty two thousand USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Awareness Consulting Network LLC who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

^{Neither GG Media Holdings LLC, TD Media LLC and their member own shares of (MDCX:US).}

^{Please see important disclosure information here:}^{https://dailyedgereport.com/disclosure/mdcx-ssdMC/#details}